PL332074A1 - Dosable administration form of controllable release of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo-[2,2,2]oct-3-yl) acetonitrile monohydrochloride - Google Patents

Dosable administration form of controllable release of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo-[2,2,2]oct-3-yl) acetonitrile monohydrochloride

Info

Publication number
PL332074A1
PL332074A1 PL97332074A PL33207497A PL332074A1 PL 332074 A1 PL332074 A1 PL 332074A1 PL 97332074 A PL97332074 A PL 97332074A PL 33207497 A PL33207497 A PL 33207497A PL 332074 A1 PL332074 A1 PL 332074A1
Authority
PL
Poland
Prior art keywords
alpha
dosable
methoxyimino
azabicyclo
oct
Prior art date
Application number
PL97332074A
Other languages
English (en)
Inventor
Susan Marie Milosovich
William Muldoon
James Albert Napper
Laurence Rousseau
Joseph Sauer
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of PL332074A1 publication Critical patent/PL332074A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
PL97332074A 1996-09-12 1997-09-08 Dosable administration form of controllable release of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo-[2,2,2]oct-3-yl) acetonitrile monohydrochloride PL332074A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619074.9A GB9619074D0 (en) 1996-09-12 1996-09-12 Composition
PCT/GB1997/002418 WO1998010762A2 (en) 1996-09-12 1997-09-08 Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride

Publications (1)

Publication Number Publication Date
PL332074A1 true PL332074A1 (en) 1999-08-30

Family

ID=10799833

Family Applications (1)

Application Number Title Priority Date Filing Date
PL97332074A PL332074A1 (en) 1996-09-12 1997-09-08 Dosable administration form of controllable release of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo-[2,2,2]oct-3-yl) acetonitrile monohydrochloride

Country Status (22)

Country Link
EP (1) EP0929301A2 (enExample)
JP (1) JP2001500150A (enExample)
KR (1) KR20000036039A (enExample)
CN (2) CN1235544A (enExample)
AR (1) AR008176A1 (enExample)
AU (1) AU724086B2 (enExample)
BR (1) BR9711734A (enExample)
CA (1) CA2265661A1 (enExample)
CO (1) CO5031291A1 (enExample)
CZ (1) CZ83299A3 (enExample)
GB (1) GB9619074D0 (enExample)
HU (1) HUP9904401A3 (enExample)
ID (1) ID19589A (enExample)
IL (1) IL128781A0 (enExample)
MA (1) MA24359A1 (enExample)
NO (1) NO991194D0 (enExample)
NZ (1) NZ334268A (enExample)
PE (1) PE2499A1 (enExample)
PL (1) PL332074A1 (enExample)
TR (1) TR199900505T2 (enExample)
WO (1) WO1998010762A2 (enExample)
ZA (1) ZA978133B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775597B1 (fr) * 1998-03-04 2001-04-20 Gattefosse Ets Sa Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication
CA2323177A1 (en) * 1998-03-11 1999-09-16 Susan Marie Milosovich Composition
DE19918325A1 (de) * 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
FR2796840B1 (fr) * 1999-07-26 2003-06-20 Ethypharm Lab Prod Ethiques Comprimes faiblement doses et procede de preparation
US6733781B2 (en) 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
PE20040134A1 (es) 2002-07-25 2004-03-06 Pharmacia Corp Forma de dosificacion de una vez al dia de pramipexol
JP4808612B2 (ja) * 2003-04-25 2011-11-02 田辺三菱製薬株式会社 アルキレンジオキシベンゼン誘導体を含む経口投与用組成物
PL1628642T3 (pl) * 2003-05-14 2007-01-31 Aptalis Pharma Ltd Kontrolowane uwalnianie lekarstwa z kompozycji odpornej in vivo na mechaniczny stres
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP2005272347A (ja) * 2004-03-24 2005-10-06 Ohara Yakuhin Kogyo Kk 固形製剤の製造方法
UA95993C2 (ru) * 2004-08-13 2011-09-26 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
UA86831C2 (uk) 2004-08-13 2009-05-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Композиція таблетки пролонгованого вивільнення, яка містить праміпексол або його фармацевтично прийнятну сіль, спосіб її виготовлення та її застосування
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
EP3955910A4 (en) * 2019-04-19 2023-01-25 Hoffman Technologies LLC. DELAYED RELEASE FORMULATION

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG48315A1 (en) * 1989-04-13 1998-04-17 Beecham Group Plc Novel compounds
GB9409718D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
AR004178A1 (es) * 1995-07-29 1998-11-04 Smithkline Beecham Plc Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma.

Also Published As

Publication number Publication date
HUP9904401A2 (hu) 2000-06-28
IL128781A0 (en) 2000-01-31
GB9619074D0 (en) 1996-10-23
CO5031291A1 (es) 2001-04-27
EP0929301A2 (en) 1999-07-21
CN1446535A (zh) 2003-10-08
TR199900505T2 (enExample) 1999-06-21
PE2499A1 (es) 1999-03-24
CZ83299A3 (cs) 1999-08-11
WO1998010762A3 (en) 1998-06-04
MA24359A1 (fr) 1998-07-01
KR20000036039A (ko) 2000-06-26
AU4128897A (en) 1998-04-02
ID19589A (id) 1998-07-23
HUP9904401A3 (en) 2001-03-28
ZA978133B (en) 1999-04-12
NO991194L (no) 1999-03-11
NO991194D0 (no) 1999-03-11
AR008176A1 (es) 1999-12-09
BR9711734A (pt) 1999-08-24
CN1235544A (zh) 1999-11-17
AU724086B2 (en) 2000-09-14
JP2001500150A (ja) 2001-01-09
CA2265661A1 (en) 1998-03-19
NZ334268A (en) 2000-10-27
WO1998010762A2 (en) 1998-03-19

Similar Documents

Publication Publication Date Title
PL332074A1 (en) Dosable administration form of controllable release of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo-[2,2,2]oct-3-yl) acetonitrile monohydrochloride
HUP0000582A3 (en) Insecticidal, acaricidal and nematocidal 8-azabicyclo[3.2.1]octane-, 8-azabicyclo[3.2.1]oct-6-ene-, 9-azabicyclo[3.3.1]nonane-, 9-aza-3-oxabicyclo[3.3.1]nonane- and 9-aza-3-thiabicyclo[3.3.1]nonane derivatives, preparation and use thereof
HUP0100059A3 (en) Novel pyridazine derivatives and drugs containing the same as the active ingredient
HU9601884D0 (en) 6-(dimethylamino-methyl)-1-phenyl-cyclohexane compounds as pharmaceutically active matarials
HUP0101043A3 (en) Controlled release oral dosage form containing [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl]acetonitrile monohydrochlorid and process for its preparation
HUP0102036A3 (en) Peroral active agent suspension and process for its preparation
EP1017980A4 (en) METHOD FOR IDENTIFYING PHARMACEUTICALLY ACTIVE COMPOUNDS
IL190120A0 (en) PREPARATION OF 9-AMINO OCTAHYDRO-6,10-DIOXO-6H-PYRIDAZINO/1,2-a//1,2/DIAZEPIN-1-CARBOXYLIC ACID DERIVATIVES
PL336315A1 (en) Derivatives of 5-aryl-3- (8-azabicyclo[3.2.1] oct-3-yl) 1,3,4- oxadiazol-2-(2h)-one, their production and therapeutic application_
IL135520A0 (en) 8-azabicyclo [3.2.1.] octane-3-methanamine derivatives, their preparation and their therapeutic application
HUP9903706A3 (en) 4,5-dihydronaphth[1,2-c]isoxazoles and derivatives thereof having cns activity, process for their preparation and pharmaceutical compositions containing the same
HK1021336A (en) Controlled release dosage form of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl)acetonitrile monohydrochloride
TR199900141T2 (xx) Bunama tedavisi ve/veya profilaksisi i�in form�lasyon.
ZA955942B (en) 4-hydroxy-3-phenylindeno[1,2-b]pyridin-2(1H)-one derivatives their preparation and the medicaments containing them
HK1035855A (en) Controlled release composition of (1-azabicyclo(2.2.2)oct-3-yl)acetonitrile monohydrochloride
IL120285A (en) Process for the preparation of 1,5-benzothiazepine derivatives, process for the preparation of the intermediate thereof and an intermediate thereof
ZA973124B (en) 3-[(1,2,3,4-tetrahydroisoquinolin-2-yl)methyl]-8-azabicyclo[3.2.1]octane derivatives, their preparation and their therapeutic application.
IL135168A0 (en) Novel pharmaceutically active compounds, their preparation and use as ece-inhibitors
IL114522A (en) Process for the preparation of alpha-(oximino)-alpha-(1-azabicyclo¬2.2.2¾oct-3-yl) acetonitrile derivatives
GB2284602B (en) Pharmaceutically active diketopiperazines
IL113398A0 (en) Use of N-isobutyl-N'-isopropyl - 9,9- pentamethylene - 3,7 - diazabicyclo [3,3,1] nonane
GB9602667D0 (en) Pharmaceutically active compounds
GB9610474D0 (en) Pharmaceutically active compounds
GB9602668D0 (en) Pharmaceutically active compounds
GB9619122D0 (en) Pharmaceutically active compounds